Estudio fase II, abierto, multicentrico, no aleatorizado para evaluar la eficacia y la seguridad de la combinacion de lapatinib, oxaliplatino y capecitabina como tratamiento neoadyuvante en pacientes HER2/ErbB2 positivo con adenocarcinoma gastrico, de la union gastroesofagica o del tercio inferior del esofago, en estadio IB-III.

Trial Profile

Estudio fase II, abierto, multicentrico, no aleatorizado para evaluar la eficacia y la seguridad de la combinacion de lapatinib, oxaliplatino y capecitabina como tratamiento neoadyuvante en pacientes HER2/ErbB2 positivo con adenocarcinoma gastrico, de la union gastroesofagica o del tercio inferior del esofago, en estadio IB-III.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2012

At a glance

  • Drugs Capecitabine (Primary) ; Lapatinib (Primary) ; Oxaliplatin (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms LAOXCAP
  • Most Recent Events

    • 08 Mar 2012 Status changed from recruiting to discontinued according to EudraCT record..
    • 28 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top